• Gold outperformed all major global bond, emerging market stock benchmarks in 2019
• Gold price increased 18.4% in 2019, expected to skyrocket due to COVID-19-related economic factors
• KGS acquires and develops historic gold mining sites, extracting remaining wealth left behind using modern technology
• KGS recently entered into two options agreements for historic mining sites with proven reserves

Kingman Minerals (TSX.V: KGS) is a Canadian mining company focused on sourcing and developing historic gold and silver properties throughout North America with the aim of using modern technology to extract remaining wealth left behind by previous generations. As the world braces for a coming recession, the price of gold is expected to reach record levels (http://ibn.fm/3rxro), positioning KGS favorably to benefit from the current bullish nature of the gold sector, which is driven mainly by investors diverting capital from less tangible assets to precious metals.

According to a report by the World Gold Council gold is experiencing its strongest gains since 2010, having risen 18.4% in 2019 and with even greater results expected this year. Besides increased market risk and weak economic growth, additional factors pressuring gold upward include lowered interest rates, increased government debt levels and fears that inflation will lower the value of fiat currency. Strong capital flows into gold-backed ETFs and large purchases of gold for central banks by governments like The Communist Party of China (http://ibn.fm/Kbpjt) and the Russian government (http://ibn.fm/zCGud) all contributed to its rise in value as the metal outperformed major global bond and emerging market stock benchmarks in 2019.

KGS is leveraging this trend through the acquisition and development of historic gold mining sites, extracting the remaining wealth safely and cost-efficiently by using new, innovative technologies unavailable to previous generations. Unlike the scraping, picking and panning techniques used in the past, KGS is leveraging technological upgrades to the extraction process at its Mohave Project and Cadillac East Properties, two historical mining sites with proven reserves left behind decades ago.

Originally discovered in the Music Mountains of Arizona during the 19th-century “Gold Rush” era, the Mohave Project comprises 20 lode claims that include the historic 167-hectare Rosebud Mine. With an option agreement in place allowing KGS to earn 100% over four years, the company has access to an estimated 664,000 ounces of gold and 2,600,000 ounces of silver (http://ibn.fm/sDVzr). Besides completing two underground reconnaissance and sampling programs, the company is also in the process of verifying previous resource estimates.

Also included in KGS’s diverse asset portfolio is the Cadillac East Property located in the Canadian province of Quebec, subject of numerous geophysical and geological surveys by private corporations and the Quebec government. Totaling 12 lode claims, KGS entered into an option agreement to earn 100% over three years with additional access to other recently identified potential targets that include silver, copper, zinc and nickel.

With a focused strategy that includes enhancing shareholder value, KGS actively engages in the business of precious metal mineral exploration, acquiring non-grassroots mineral properties throughout North America and advancing their production through technological innovation. As the value of gold continues to climb, KGS is poised to benefit from its increase in price along with renewed interest in mining companies by investors looking to divert capital into the precious metal sector.

For more information, visit the company’s website at www.KingmanMinerals.com.

NOTE TO INVESTORS: The latest news and updates relating to KGS are available in the company’s newsroom at http://ibn.fm/KGS

• Industry article notes that cryptocurrency mining space is big-growth industry
• Joint venture allows ISWH to collaborate with experienced Bit5ive team
• Company plans to run profitable, efficient crypto-mining projects; take advantage of incredible growth projected for crypto market

In a world where some of today’s fastest-growing industries weren’t even around a few years ago, ISW Holdings (OTC: ISWH), a brand-management portfolio company with diverse partnerships, appears to know exactly where to focus its efforts. At least that’s what a recent Journal Transcript article is reporting.

“New industries are appearing everywhere as the 21st century starts to stretch its legs. Maybe we don’t have flying cars yet. But we do have big-growth industries that didn’t exist at all 20 years ago. Autonomous vehicle AI sensors, Internet-of-Things Logistics, recreational cannabis dispensary, genetic engineering data analytics, and cryptocurrency mining equipment are a few examples,” stated the article, titled “ISW Holdings Targets the Crypto Mining Cycle” (http://ibn.fm/FJ9ns).

The article goes on to report that ISWH is entering the crypto mining space via a recent joint venture partnership with Bit5ive LLC; the two companies plan to develop, run and sell turnkey mining solutions.

“The turnkey crypto mining solutions revolution is upon us,” the article concludes. “And it couldn’t come at a more interesting time for this emerging industry — when the overall mining equipment space is looking more and more like it stands in the very early innings of a long-term growth cycle driving by product cycles, depleted supplies in secondary markets, under-revved production rates, and rapidly growing demand. It may well be the case that ISW Holdings Inc got into this game at precisely the right time.”

In fact, the bitcoin technology market, valued at $293.66 million in 2019, is expected to reach $477 million by 2025, according to Mordor Intelligence (http://ibn.fm/q4WJg). “We are incredibly excited to expand our current portfolio and move into what we believe is a sector poised for strong technological and financial growth,” said ISWH president and chairman Alonzo Pierce. “This new joint-venture agreement enables us to collaborate with the experienced team at Bit5ive to innovate the infrastructure needed to run profitable, efficient crypto-mining projects, and to take advantage of the incredible growth projected for the crypto market.”

Based in Nevada, ISW Holdings is a diversified portfolio company comprised of essential business lines that serve consumer product demands. The company’s expertise lies in strategic brand development and early-growth facilitation, as well as brand identity through its proprietary procurement process. Together with its partners, ISWH seeks to provide a structure that meets large scalability demands as well as anticipated marketplace needs. ISWH maneuvers its proprietary companies through critical stages of market development, which includes conceptualization, go-to-market strategies, engineering, product integration and distribution efficiency.

For more information, visit the company’s website at www.ISWHoldings.com.

NOTE TO INVESTORS: The latest news and updates relating to ISWH are available in the company’s newsroom at http://ibn.fm/ISWH

• Psychedelics have shown positive results for treatment of mental health conditions including anxiety, depression, PTSD, addiction, eating disorders, ADHD
• Big pharma failed to bring drug innovations in mental health space; psychedelics may satisfy vast unmet need
• With secured delivery mechanisms and manufacturing contract in hand, Cybin appears well positioned to capitalize on growing market trend

As big pharma has failed to bring groundbreaking drug innovations into the mental health space, new data increasingly shows that psychedelics may close this gap, creating an entirely new market of safe and effective psychedelics medicines (http://ibn.fm/M6gla). Cybin Corp., a leading Canada-based, life-sciences company, is focused on developing pharmaceutical-grade psychedelic products and appears ideally positioned to make the most of this groundbreaking research.

Found in certain species of mushrooms, psilocybin — the main compound of pharmaceutical psychedelic products — has shown positive results for the treatment of anxiety, depression, PTSD, addiction, eating disorders and ADHD. As a research-first, life-science company, Cybin views mushroom-derived psychedelic compounds as brain boosters that have the potential to rebuild pathways and break negative patterns.

Psilocybin offers a scientific breakthrough in treating these conditions as it is rapidly metabolized to psilocin, which impacts serotonin receptors in the brain. With an increasing number of scientific research and clinical studies documenting that this naturally occurring, nonhabit-forming, psychedelic compound offers considerable positive effects in the treatment of mental health and other conditions, the serotonergic psychedelics today are being increasingly viewed in a new light as society embraces these benefits. Leading the wave of the mushroom-based products revival, Cybin has been laying the foundation for the moment pharmaceutical psychedelics achieve recognition in North America and worldwide.

Cybin is potentially poised to be the first company to develop psilocybin-based medicine designed to target major depressive disorders. Currently involved in structuring a clinical study that will be conducted through an academic partner in the Caribbean, Cybin has already filled a patent application for a diverse set of delivery mechanisms, identified synthetic psilocybin active pharmaceutical ingredients (“API”) sources and obtained a contract with a synthetic psilocybin oral film manufacturer.

It currently takes researchers around 12 months to get psilocybin for their studies as they wait for regulatory approval. In contrast, Cybin has secured 25mg API available immediately, which is sufficient for Phase 2a and Phase 2b trials in patients with moderate depressive disorder. The company is also in the process of developing its own proprietary API for psychedelic clinical research, with an initial focus on psilocybin and with a view of expanding to other analogs found in mushrooms (http://ibn.fm/Dh1Bp).

Cybin operates in the functional mushroom market with a goal to develop fungi-derived psychedelic and medicinal products to treat mental illness and other health conditions. The business model of this early-stage, life-sciences company includes two wholly owned core subsidiaries: Serenity Life Sciences, focused on advancing research and development of psilocybin-based psychedelic pharmaceutical products, and Natures Journey Inc., developing medicinal nonpsychedelic nutraceutical products.

According to the World Health Organization, more than 700 million individuals around the world are affected by some type of mental illness, addiction, or eating disorder. Clearly, there is a considerable unmet medical need for effective treatments for these types of mental health conditions. Led by a proven team of professionals with extensive experience in clinical trials and commercialization of new drugs, Cybin is emerging as a leader in the psychedelics space, poised to leverage its robust scientific capabilities to capitalize on the significant psychedelics-growth potential.

For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to Cybin are available in the company’s newsroom at http://ibn.fm/Cybin

• SHRG announce year-end numbers that top previous record-setting totals
• Revenues for FY 2020 total $131.4 million, a 53% increase over FY 2019
• CEO notes that talented personnel, enhanced software, additional infrastructure stand to benefit the company long term

Sharing Services Global Corporation (OTCQB: SHRG), a publicly traded company dedicated to maximizing shareholder value through the acquisition and development of innovative companies, products and technologies in the direct-selling sector and other industries, announced its FY 2020 revenue numbers, including an increase of more than 50% over last year’s numbers (http://ibn.fm/sqe8i). SHRG announced the figures in conjunction with filing its annual SEC 10-K report.

“The last 12 months have been challenging but rewarding for everyone involved with our company,” said SHRG CEO John “JT” Thatch. “Not only have we demonstrated strong sales growth with our health and wellness products during some difficult times, but as a team we have positioned ourselves with talented personnel, enhanced software and additional infrastructure, which we feel will benefit us in our long-term mission.”

Highlights of the report include revenues of $131.4 million for the fiscal year ended April 2020; the figure represents an increase of approximately $45.5 million, or a 53% increase, compared to fiscal year 2019 revenues of $85.9 million. This fiscal year continues the pattern of record-breaking numbers for the company, which has reported cumulative sales revenues of over $225 million since the December 2017 launch of its Elevacity products.

SHRG’s proprietary line of products, which include functional beverages and nutritional supplements, is distributed through its Elevacity subsidiary. The exclusive products are carefully formulated and developed by a team of doctors, pharmacists, chemists, naturopaths, food scientists and nutrition experts, and are designed to offer a wide range of benefits.

What makes the products truly distinctive is the company’s D.O.S.E. philosophy: Each product contains a careful combination of four ingredients (dopamine, oxytocin, serotonin and endorphins) that the company calls “happiness hormones.” Research has proven that these hormones promote feelings of happiness and well-being. This philosophy underlies the company’s continued commitment to offering life-changing products and opportunities.

“We continue to explore new products and services that will benefit our hardworking distributors, loyal customers and valued shareholders, while looking at further expansion efforts before the end of this year,” Thatch concluded.

The Sharing Services combined platform currently leverages the capabilities and expertise of various companies that market and sell products direct to the consumer through independent contractors. Two of its primary divisions include Elevacity Holdings LLC., the parent of its wholly owned subsidiary, Elevacity U.S. LLC, a health and wellness products company, and Elepreneurs Holdings LLC., the parent of its wholly owned subsidiary, Elepreneurs U.S. LLC, a sales and marketing company based on utilization of independent contractor distributors who sell the Elevacity product line.

For more information, visit the company’s websites at www.SHRGInc.com, www.Elevacity.com and www.Elepreneur.com.

NOTE TO INVESTORS: The latest news and updates relating to SHRG are available in the company’s newsroom at http://ibn.fm/SHRG

• Data protection laws now adopted by nearly 90 countries and independent territories
• SRAX’s BIGtoken platform provides transparent solution that compensates users while providing fee-based access to marketers

Increasing privacy concerns over the use of personal data have played a large part in driving users away from many popular social media platforms that include the loss of over 15 million users by Facebook in less than two years (http://ibn.fm/eFTBq). Accordingly, nearly 90 countries and independent territories throughout the world have now adopted comprehensive data protection laws that aim to protect the public from marketers that obtain and sell data without their explicit permission (http://ibn.fm/WzCxY). SRAX Inc. (NASDAQ: SRAX), a digital marketing and consumer data management technology company, evades this problem through its transparent BIGtoken network that compensates millions of users when they opt in to sell access to their data while simultaneously creating valuable data sets that marketers can access for a fee.

Dubbed by some analysts as the new “oil” powering the digital economy, the importance of data is now reaching mainstream consciousness where consumers are increasingly becoming aware that their data is generating billions of dollars for marketers. Encouraged by SRAX’s message to “take back what’s rightfully yours”, over 16.7 million users answered that call by downloading the BIGtoken application and selling their data in exchange for cash and gift cards.

“Big marketers are really interested in this,” said CEO and founder Christopher Miglino in a recent interview with Brian Calle on the LA Weekly Podcast (http://ibn.fm/dFJrf). “They don’t want to buy bad data anymore. They want to buy data from consumers that have said ‘yes, you have the right to market to me’, so we’ve found ourselves in a unique spot.”

On the client side, SRAX provides a specialized suite of tools offering a valuable competitive advantage for brands in the CPG, investor relations, luxury goods, and lifestyle verticals. Through the integration of several marketing aspects into one platform, SRAX answers the demand for quality data by giving marketers the power to target and access specific niche groups across 25,000 unique points of segmentation in almost every industry. Through a unique interface that gives users the power to submit specialized queries – such as location and purchase history – SRAX’s proprietary technology empowers marketers to unlock the power of consumer data for use in precision marketing strategies that better reach and serve audiences.

SRAX’s mission is to provide everyone on the Internet with choice, transparency and compensation for their digital data. Founded in 2010, the publicly-traded Company has developed a deep understanding of the limited awareness consumers face when it comes to the data they produce online. By offering choice and compensation to BIGtoken users, SRAX is able to provide solutions that benefit both sides in the market for consumer data.

For more information, visit the company’s website at www.SRAX.com.

NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

• DarioHealth Corp. is providing innovative solutions to medical patient care through its technology enabled remote patient monitoring platform (“RPM”), which it believes will save medical providers time while allowing them to better control care
• The company announced its first two remote patient monitoring agreements in North America last month
• On July 20, DarioHealth announced a strategic partnership that will allow the company to expand the reach of its remote patient care management internationally, targeting markets in the United Kingdom and Ireland
• The ongoing COVID-19 pandemic has made tech enabled remote patient care increasingly popular as a general solution to maintaining health measures while minimizing the risk of virus transmission
• The remote patient monitoring services market is expected to grow at a CAGR of 17.8 percent between 2019 and 2026

Digital therapeutics innovator DarioHealth (NASDAQ: DRIO) is building bridges that will help it cross over the Atlantic Ocean and begin serving Europeans with the company’s health monitoring solution. The company announced July 20 that it has entered into a strategic partnership with Williams Medical to make the DarioHealth Remote Patient Monitoring (“RPM”) digital therapeutics platform available to healthcare professionals across the United Kingdom and Ireland (http://ibn.fm/ikMWo). The DarioHealth Remote Patient Monitoring platform allows treating physicians to remain involved in the care management of their patients in between office visits, which the company believes will lessen the workload of healthcare providers while potentially preventing unnecessary and unplanned hospital visits and securing the position of the general physician as the primary source of medical advice. The digital therapeutics platform integrates the operation of the company’s existing open platform, user-responsive app technology, and the DarioEngage coaching platform to help physicians and large provider groups work within the framework of approved of remote patient monitoring billing codes, according to the company. The platform personalizeshealthcare, delivering occasional “nudges” to patients according to their needs and live responses to health situations reported by AI-enabled smart tech in patients’ medical devices (http://ibn.fm/n6ixP). “We are very excited about this partnership between DarioHealth and Williams Medical as this aligns with our international growth initiative by offering our world-class RPM platform to physicians outside of the United States,” DarioHealth COO Dror Bacher stated. “Williams’ in-depth understanding of the UK and Irish healthcare markets and strong presence in the primary care arena creates an ideal opportunity for us to deliver a best-in-class RPM solution to general practices and patients.” The agreement follows on the heels of last month’s announcement that DarioHealth had signed its first two remote patient monitoring agreements in North America (http://ibn.fm/HQubx). The benefits of remote-access telehealth in general has become increasingly evident as the COVID-19 pandemic has lengthened out its duration. Private insurers have seen telemedicine claims grow by 4,347 percent year-over-year during the global crisis (http://ibn.fm/AO3lU). Personalized, AI-facilitated reporting of and responsiveness to patients’ medical conditions and care management is a technology-heavy subset of the virtual health management market. The digital diabetes management market subset itself is projected to record a CAGR of 17.8 percent between 2019 and 2026, according to Data Bridge Market Research (http://ibn.fm/PV4Yp). If telemedicine services remain popular with patients and insurance providers continue to be responsive to reimbursing telehealth claims as a general expression of the trend, market analysts at McKinsey & Company predict that the market could reach a $250 billion capitalization (http://ibn.fm/SpuUG). For more information, visit the company’s website at www.DarioHealth.com. NOTE TO INVESTORS: The latest news and updates relating to DRIO are available in the company’s newsroom at http://ibn.fm/DRIO

• Gold prices continue to rally due to economic conditions resulting from COVID-19 and other global events
• Gold prices rose by nearly 20% in 2019, projected to continue in 2020
• KGS increasing gold production at historic gold mining sites using new technologies
• Company entered into option agreements to obtain 100% ownership of Mohave Project and Cadillac East Property

Gold investment continues to increase as a result of the current economic landscape characterized by record unemployment, stock market volatility, and trillion-dollar stimulus packages that are sending public debt to unprecedented levels. Kingman Minerals (TSX.V: KGS), a Canada-based mining company engaged in the acquisition, exploration and development of gold and silver properties in North America, is set to benefit from this trend as investors continue to divert significant holdings into precious metals as a defensive measure against inflation, currency devaluation and the falling value of less tangible assets.

Gold prices rose by as much as 20% in 2019 to a peak of $1,549 per ounce by September (http://ibn.fm/mCqcG). Analysts at the Financial Post (http://ibn.fm/g9wQ4) believe 2020 will be another record year due to the same factors that drove the price up in 2019—including global trade issues, central bank interest rate cuts and volatile investment markets.

According to the World Gold Council, gold is one of the most liquid assets in the world, trading at an average daily volume of $112 billion – almost 5 times more than the Dow Jones Industrial Average (http://ibn.fm/bbSJn). Its liquidity makes it immensely popular with investors, particularly during periods of increased government spending, lowered central bank interest rates, and volatile investment markets.

KGS is leveraging this challenging economic situation by increasing gold production on historic gold mining sites using new technologies that extract the remaining wealth safely and cost-efficiently. With a focus on sourcing and developing high-quality properties in historically favorable mining jurisdictions, KGS recently entered into option agreements to purchase 100% interest in two key portfolio properties: the Mohave Project and the Cadillac East Property.

Located in the Music Mountains in Mohave County, Arizona, the Mohave Project comprises 20 lode claims that include the historic 167-hectare Rosebud Mine that was originally discovered during the 19th-century “Gold Rush” era. The Cadillac East Property is located in Canada’s Quebec province and consists of 12 gold claims in addition to other precious metals revealed in a soil program that identified silver, copper, zinc and nickel prospects. Despite the fact that most of the accessible resources have already been extracted from these properties, KGS plans to use modern mining techniques to tap into the wealth left behind by previous mining generations.

Based in Canada, KGS is formerly engaged in the acquisition, exploration and development of gold and silver properties in North America. With a strong focus on sourcing and developing properties of high quality with significant mining potential, KGS is poised to benefit from the volatile economic landscape through its strategy of developing a diverse portfolio of low-cost, lifelong mining assets.

For more information, visit the company’s website at www.KingmanMinerals.com.

NOTE TO INVESTORS: The latest news and updates relating to KGS are available in the company’s newsroom at http://ibn.fm/KGS

• Pharmaceutical and health care services company Trxade Group Inc. is enjoying growing attention as it continues to roll out remote-access medical solutions that are suited to the ongoing COVID-19 pandemic and the need to prevent virus transmission
• The company will announce its second quarter financial report July 27 following the close of markets that day
• Telehealth claims to private insurers have grown by 4,347 percent year-over-year during the past few months in which the pandemic has swept the planet
• Trxade Group’s introduction of the Bonum Health Hub and online pharmaceutical ordering and delivery services has driven the company’s customer responsiveness during the pandemic
• The company’s core focus has been to sustain independent pharmaceutical and health care providers by helping them gain access to transparency in drug pricing and other aspects of business so they can be competitive with larger chains

Pharmaceutical services provider Trxade Group (NASDAQ: MEDS) has seen its star rising during recent months while working to raise awareness of its medical consultation and prescription drug solutions. As the spread of the novel coronavirus unexpectedly reached pandemic proportions and battered world economies with its infectious spread and the resulting infection-fighting policies, Trxade Group has advanced measures that help patients and providers continue to access resources through a virtual environment safe from contagion.

On July 27, Trxade Group’s management will host a conference call following the close of trading at 5 p.m. EDT to discuss the company’s 2020 second quarter financial results, which will conclude with a Q&A opportunity for participants. Details published by the company provide phone-in numbers for U.S. and international participants as well as the conference ID and the address for the webcast (http://ibn.fm/hTZJs).

A playback of the conference call will be available through Aug. 27, as will the webcast. The webcast will also be accessible under the company website’s investor relations heading.

Trxade Group uplisted to the Nasdaq exchange earlier this year (http://ibn.fm/01GnB) and last month it gained inclusion on this year’s Russell’s Microcap Index (http://ibn.fm/lH3UN), measures that are helping to raise the company’s profile within the investment community. Investment services firm Taglich Brothers, Inc. has begun providing coverage to Trxade through its research division as well to create and distribute research reports on the company and its market (http://ibn.fm/2EcWN).

Even before the emergence of the pandemic, Trxade Group was introducing and bolstering services that help small, independent pharmacies to shop competitively for medications, patients to have those medications delivered promptly and safely without the need for traveling to a pharmacy, as well as medical providers to be accessible through smart-tech secured telemedicine applications.

Strategic acquisition of Internet drug outlet company Community Specialty Pharmacy, LLC, (http://ibn.fm/wXTOK) and Bonum Health (http://ibn.fm/BMKiC) has allowed the company to lay the groundwork for an increased demand on telehealth services.

During the COVID-19 crisis, telehealth services have seen astronomical expansion. Telehealth claims to private insurers have grown 4,347 percent year-over-year (http://ibn.fm/dD2oy), CVS Health saw 600 percent growth in telehealth and virtual visits through its MinuteClinics in the first quarter of 2020 (http://ibn.fm/Zl83M), Blue Cross and Blue Shield of Tennessee saw 50 times more telehealth visits in May compared to their normal amount (http://ibn.fm/2P1Cd) and Blue Cross of Idaho processed more than 90,500 telehealth claims between March and June, with telehealth now representing more than one-quarter of all claims (http://ibn.fm/gpdww).

If the telemedicine services remain popular with patients and insurance providers continue to be responsive to reimbursing telehealth claims, market analysts at McKinsey & Company forecast a $250 billion market (http://ibn.fm/C5J8m) while Frost & Sullivan projects a seven-fold increase by 2025 (http://ibn.fm/RwJeh).

For more information, visit the company’s website at www.TrxadeGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to MEDS are available in the company’s newsroom at http://ibn.fm/MEDS

• PowerBand Solutions has begun reporting new revenue in the wake of its launch of auto loan origination in Texas and Florida this month
• The company expects to expand its lending program to California and other markets nationwide in the near future
• PowerBand Solutions is a fintech innovator whose responsive online platform promotes auto purchases through a utility that facilitates financing and inventory paperwork, vehicle inspections and auction negotiations as well as the monetary transaction
• As the online sales network grows nationwide, it shows the company’s capacity to respond to unforeseen calamitous market forces such as the global COVID-19 pandemic, which has hindered face-to-face transactions

PowerBand Solutions (TSX.V: PBX) (OTCQB: PWWBF) (FRA: 1ZVA) is rapidly emerging as a fintech innovator singularly equipped to help car and truck buyers nationwide complete purchases through an online platform that emphasizes a simplicity, speed, and cost-efficiency never before available through a virtual auto sales network.

On the heels of its July 13 announcement that its U.S. leasing division, MUSA Auto Finance, LLC, would begin originating auto loans in Texas and Florida (http://ibn.fm/x2fGu), PowerBand Solutions is confirming that the company has begun generating revenue from lease originations in those markets and that the company will soon expand its lease programs to California and other markets across the United States.

“I’m happy to report that our virtual transaction system is working as planned and completing leases and financing in the United States,” PowerBand CEO Kelly Jennings stated in a July 16 update (http://ibn.fm/K68l1). “The Company has made considerable and carefully targeted investments in our virtual transaction platform. … I thank our strategic partners and investors for their support, and am proud that we are now offering people a way to acquire and sell a vehicle from any location, as easily as you can now buy a product from Amazon on your smart phone.”

The news also provides confirmation that consumers continue to invest in the auto industry despite economic difficulties brought on by a a global pandemic that has seriously wounded marketplace vitality, described as “the largest economic shock the world has experienced in decades” (http://ibn.fm/CvCzY).

The company’s platform has helped sellers and consumers continue to interact with each other easily during the pandemic era despite restrictions on face-to-face transactions in order to reduce infection. The platform streamlines not only the transfer of money but also financing and inventory paperwork, vehicle inspections and auction negotiations, and does so through virtual connections.

The loan origination was made possible thanks to a $300 million funding agreement with a national financial institution chartered with the federal government.

Jennings reported that PowerBand finds itself well positioned to achieve ongoing revenue growth this year and in the years to come in spite of the market obstacles caused by the pandemic.

The company states it has also issued 76,923 common shares to bring in an additional $11,538.45 through the exercise of warrants at a price of $0.15, raising its common shares total to 112,255,388 issued and outstanding. More than 23 million warrants and 12 million options create the potential for additional backing.

Total revenue for the first quarter of 2020 increased from $554,097 to $615,432 year-over-year, according to the company’s condensed interim consolidated financial statements filed with SEDAR (http://ibn.fm/sxNNM).

For more information, visit the company’s website at www.PowerBandSolutions.com.

NOTE TO INVESTORS: The latest news and updates relating to PWWBF are available in the company’s newsroom at http://ibn.fm/PWWBF

• POAI completes acquisition designed to accelerate commercialization of proprietary AI-driven drug discovery, development
• Strategic move allows for one-of-a-kind, end-to-end ‘discovery machine’ that can rapidly generate potential therapeutic candidates
• Company to offer new capability to pharmaceutical company customers in revenue-generating projects later this year

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine, has completed its acquisition of Quantitative Medicine (“QM”) (http://ibn.fm/vqmwL). POAI signed a letter of intent to acquire QM, a biomedical analytics and computational biology company, in January (http://ibn.fm/4iRTV). The strategic move should accelerate the commercialization of Predictive Oncology’s proprietary AI-driven drug discovery and development.

“This acquisition will enable us to further leverage our unique database of drug-response and genomics profiles that our subsidiary, Helomics, has gathered from more than 150,000 cancer cases over more than 10 years of clinical testing,” said POAI CEO Dr. Carl Schwartz. “Integrating QM’s proven machine-learning platform, CoRE, with our proprietary database of drug response and genomics profiles is expected to revolutionize the role of our AI-driven predictive models in the discovery and development of new anti-cancers.

“We will be able to more quickly understand how specific types of tumors react to cancer drug therapies,” Schwartz continued. “This will allow our customers to accelerate the development and commercialization of personalized patient treatments that dramatically improve patient outcomes. We intend to offer this new capability to our pharmaceutical company customers in revenue generating projects this year.”

Founded by Dr. Robert Murphy and Dr. Joshua Kangas, both of Carnegie Mellon University, QM has developed a novel, computational drug-discovery platform called CoRE. CoRE is designed to dramatically reduce the time, cost and financial risk of discovering new therapeutic drugs by predicting the main effects of drugs on target molecules that mediate disease.

“CoRE is a predictive model-building platform for drug screening and optimization campaigns that uses hybrid machine learning approaches to build predictive models rapidly and drive wet-lab experimentation,” said Schwartz. “Unlike the approach of many AI companies working purely ‘in silico,’ our approach will unite the CoRE approach with our PDx tumor-profiling platform and tumor-data database, allowing for a one-of-a-kind, end-to-end ‘discovery machine’ that can rapidly generate potential therapeutic candidates in a cost-effective manner. Therapeutic candidates developed by this iterative AI and experiment cycle can be fast-tracked, since there will already be demonstrated activity in preclinical laboratory tests rather than just a computer model.”

The acquisition was completed in an all-stock transaction valued at approximately $1.8 million, Under the terms of the purchase agreement, POAI issued 954,719 shares of common stock at a valuation of $1.833 per share.

POAI is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through the company’s Helomics division, the company leverages its unique, clinically validated patient derived (“PDx”) smart tumor profiling platform to provide oncologists with a road map to help individualize therapy. In addition, the company is utilizing artificial intelligence and its proprietary database of over 150,000 cancer cases tumors to build AI-driven models of tumor drug response to improve outcomes for the patients of today and tomorrow

For more information, visit the company’s website at www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI